Insight Pharma Reports Announces Biomarkers in Alzheimer’s Disease Report

NEEDHAM, Mass. - Aug. 25, 2014 - PRLog -- Insight Pharma Reports, a scientific report leader for over 15 years, released a new report on Biomarkers in Alzheimer’s Disease. Biomarkers in Alzheimer’s Disease is focused on biomarker identification and development in patients with Alzheimer’s Disease. This report focuses on the Alzheimer’s Disease space featured in the parent report, highlighting several biomarker targets under investigation and the progress that has been made in the industry. With regards to employing the use of biomarkers for Alzheimer’s Disease, Biomarkers in Alzheimer’s Disease captures market growth of biomarkers, advantages, disadvantages, and validation techniques.

Experts interviewed in this report include:

· Dr. Jens Wendland, Head of Neuroscience Genetics, Precision Medicine, PharmaTherapeutics, Pfizer Worldwide R&D

· Dr. Howard J. Federoff, Executive Vice President for Health Sciences, Georgetown University

· Dr. Andreas Jeromin, CSO and President of Atlantic Biomarkers


Also available in this report is extensive survey data exclusively conducted for this report. Illustrated by 30 figures captured in an in-depth analysis, this section features insight into targets under investigation, challenges, advantages, and desired features of future diagnostic applications.

Insight Pharma Reports also put together a table of clinical trial information and pipeline data from multiple databases related to Alzheimer’s Disease. This table features companies, targets, clinical phases, and brief target/product descriptions.

For more information and to purchase this Insight Pharma Report, visit: http://www.insightpharmareports.com/biomarkers-in-alzheim...

or contact Kerri Kelley at kkelley@healthtech.com or 781-972-1347.

About Insight Pharma Reports

Insight Pharma Reports are written by experts in consulting and industry who collaborate with us to provide a series of reports that evaluate the salient issues in pharmaceutical technology, business, and therapy markets. Insight Pharma Reports are used by leading pharmaceutical, biotech, diagnostic, consulting, and financial companies to keep abreast of the latest advances in pharmaceutical R&D, their potential applications and business impacts, and their current and future position in the marketplace. Insight Pharma Reports is a division within Cambridge Healthtech Institute.  http://www.InsightPharmaReports.com

Insight Pharma Reports offers our Affiliated Reports Collection which provides a repository of additional scientific and business resources. For more information, visit http://www.insightpharmareports.com/affiliatedreports/